Dublin, Ireland, June 4, 2020
Inflection Biosciences Ltd, a company developing innovative small molecule therapeutics for the treatment of cancer, today announced the appointment of Martin Dreyling, M.D., Professor of Medicine and head of the lymphoma programme in the Department of Medicine III, LMU Hospital, Munich, to its Oncology Advisory Panel.
Professor Martin Dreyling commented “I’m very much looking forward to working with the Inflection Biosciences team and helping them as they progress their unique dual targeting program IBL-202, into the clinic. The rationale for targeting both PIM kinase and PI3K in B-cell lymphomas is compelling and supported by a series of preclinical studies. IBL-202 may ultimately provide a further treatment option for patients suffering from a variety of cancers.”
Murray Yule, Chief Medical Officer at Inflection Biosciences, commented “We are delighted to appoint Professor Dreyling to our Oncology Advisory Panel. He is an internationally renowned scientist leading many of the recent therapeutic advances in B-cell lymphomas. His track record in the translation of novel anticancer agents into the clinic is unparalleled. We believe that his participation will assist us greatly in delivering on the therapeutic potential of IBL-202.”
Martin Dreyling is Professor of Medicine and head of the lymphoma programme in the Department of Medicine III, LMU Hospital, Munich. He studied at the Universities of Düsseldorf, Giessen, Tübingen and Würzburg, and completed his clinical training at the Universities of Bonn, Münster, Göttingen and Munich. In addition, he was visiting scientist at the University of Chicago.
Prof. Dreyling is coordinator of the European MCL Network and president elect of the German Lymphoma Alliance. He has co-authored numerous scientific papers, book chapters and abstracts in international peer-reviewed journals. About Inflection Biosciences
Inflection Biosciences Ltd is developing small molecule therapeutics for the treatment of cancer. The company's pipeline was licensed from the Spanish National Cancer Research Centre (CNIO). IBL-202 is a first-in-class, dual PIM kinase and PI3K inhibitor in development for B-cell malignancies, AML and multiple myeloma. The IBL-100 series comprises selective pan-PIM kinase inhibitors. The partnered pipeline comprises AUM302, a PIM/PI3K/mTOR inhibitor being developed by AUM Biosciences. For more information please visit www.inflectionbio.com
For Further Information Contact:
Darren Cunningham, Chief Executive Officer
Inflection Biosciences Ltd
dcunningham@inflectionbio.com
+353 (0)1 4003615